Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Ladoire
Sylvain
S
Department of Medical Oncology, Georges François Leclerc Center, Centre de Recherche INSERM 866, Faculté de Médecine, Dijon, France. sladoire@cgfl.fr
Eymard
Jean Christophe
JC
Zanetta
Sylvie
S
Mignot
Grégoire
G
Martin
Etienne
E
Kermarrec
Isabelle
I
Mourey
Eric
E
Michel
Frédéric
F
Cormier
Luc
L
Ghiringhelli
François
F
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage; D017211:Treatment Failure; D016896:Treatment Outcome
D043823:Taxoids; D000077143:Docetaxel; D003520:Cyclophosphamide; D011239:Prednisolone; D017430:Prostate-Specific Antigen